Boston Scientific Supports Successful Conclusion of CCAS 2023, Powering a New Era for China's Electrophysiology Industry

KunmingAugust 2, 2023PR Newswire -- Recently, the 14th China Cardiac Arrhythmia Summit (CCAS 2023), hosted by the Shenzhen Yixin Charity Foundation and the Ivy League of High-end Medical Talents in Beijing, and academically supported by the Asian Heart Rhythm Society, successfully concluded. Boston Scientific participated in and supported various distinctive sessions including China's New Originals, Female Physicians Special Session, Complex Cases Special Session, Pulse Ablation Special Session, and Complications Special Session. The aim was to explore the clinical application of Pulse Field Ablation (PFA) technology with frontline operators, investigate cutting-edge trends in cardiac electrophysiology, further promote the healthy development of core electrophysiology technologies in China, and help the Chinese electrophysiology industry "pulse" towards a new future.

On July 29, during the Pulsed Field Ablation session, Professor Yao Yan from Fuwai Hospital, Chinese Academy of Medical Sciences, attended and served as the chairman, while Professor Gao Bingbing, Professor Wang Xianqing, and Professor Zhong Jingquan (listed in alphabetical order by surname) served as moderators. During the conference, Professor Peng Yucheng shared an "Interpretation of Real-World Clinical Evidence for the FARAPULSE Pulsed Field Ablation System" and introduced the iteration of pulsed field ablation technology inspired by direct current ablation, as well as its improvements in controllability, safety, and efficiency. Subsequently, several experts who previously participated in the "Pulsed Field Ablation Pilot Program" at Boao Super Hospital in Hainan gave presentations on "Case Reports of PFA Applications." Through real case studies, they shared the clinical benefits of PFA technology for patients from multiple perspectives.

Professor YAO Yan, Director of the Arrhythmia Center at Fuwai Hospital, Chinese Academy of Medical Sciences

Compared with traditional radiofrequency and cryoablation, pulsed field ablation (PFA) technology is tissue-selective. Its injury mechanism involves irreversible electroporation rather than thermal heating or cooling, which reduces the impact on adjacent structures due to its high selectivity for myocardial tissue, significantly minimizing complications. Meanwhile, the FARAPULSE Pulsed Field Ablation System’s ablation catheter, available in both flower-like and basket-shaped forms, addresses ablation on both the inner pulmonary veins and the pulmonary vein antrum, making the procedure more comprehensive. The electric field generator of the FARAPULSE system delivers bipolar bidirectional wave pulses with stable clinical performance and well-established product parameters, reinforcing the concept that "Not all PFAs are created equal."

Moreover, during this conference, Boston Scientific created a distinctive and innovative interactive space for the FARAPULSE Pulsed Field Ablation System. This marked the product's first official appearance on a high-end academic platform in China, attracting over a hundred experts to visit. Through hands-on experience with the catheter samples of the FARAPULSE Pulsed Field Ablation System and learning about the biophysical principles of pulsed field ablation, several industry experts expressed surprise at this highly efficient and safe technology. They also conveyed their anticipation for it to elevate electrophysiology in China to new heights.

FARAPULSE Pulsed Field Ablation System Innovation Interactive Space

During the conference, Ms. Zhang Jun, President of Boston Scientific Greater China, attended and delivered a speech. She stated, "The three-day conference has built a high-quality platform for learning and exchange for frontline practitioners serving patients across China, which aligns perfectly with Boston Scientific's long-term commitment to empowering practitioners. In addition to continuously introducing innovative products, we are also dedicated to supporting training programs for young practitioners, sharing the value of cutting-edge technological innovations with our practitioners, accelerating the adoption of innovative techniques, with the aim of deeply participating in and actively promoting the advancement of China's medical services towards high-quality development."

Boston Scientific Greater China President Zhang Jun

About Boston Scientific

Boston Scientific Corporation is committed to innovation for life. We are dedicated to innovative medical solutions that improve the lives of patients worldwide. For over four decades, Boston Scientific has consistently led the global medical technology industry by delivering a wide range of high-performance medical solutions. These solutions address critical treatment needs for a broad patient population while reducing healthcare costs.

About Boston Scientific Greater China

Boston Scientific established its China headquarters in Shanghai in 1997 and currently has branch offices in Beijing, Guangzhou, Chengdu, Hong Kong, and Taipei. The company's core business areas include interventional cardiology, structural heart disease, cardiac rhythm management, electrophysiology, endoscopic intervention, oncology intervention, peripheral intervention, urology, respiratory intervention, otolaryngology, and neuromodulation. Upholding its tradition as an innovation leader, Boston Scientific is committed to becoming a respected medical technology company that meets the needs of doctors and patients, while demonstrating innovative vitality by providing high-quality medical products and services for prevention, diagnosis, and treatment. For more detailed information, please visit the company’s website:www.bostonscientific.cn